Stockscreener 앱 받기
1.395
7.57%
-0.125
전일 마감가:
$1.52
열려 있는:
$1.46
하루 거래량:
396.26K
Relative Volume:
0.55
시가총액:
$23.82M
수익:
-
순이익/손실:
$-39.14M
주가수익비율:
-0.2337
EPS:
-5.97
순현금흐름:
$-28.20M
1주 성능:
-9.35%
1개월 성능:
+2.55%
6개월 성능:
+82.70%
1년 성능:
-83.90%
1일 변동 폭
$1.36
$1.4753
1주일 범위
$1.36
$1.64
52주 변동 폭
$0.65
$12.84
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
명칭
Citius Pharmaceuticals Inc
전화
(908) 967-6676
주소
11 COMMERCE DRIVE, CRANFORD, NJ
CTXR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
1.40 | 28.08M | 0 | -39.14M | -28.20M | -5.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.16 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.15 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.92 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.09 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.56 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-30 | 업그레이드 | D. Boral Capital | Hold → Buy |
| 2021-11-30 | 개시 | Maxim Group | Buy |
Citius Pharmaceuticals Inc 주식(CTXR)의 최신 뉴스
Why Citius Pharmaceuticals Inc. stock could rally in 2025Global Markets & Reliable Intraday Trade Plans - newser.com
How Citius Pharmaceuticals Inc. (47N0) stock reacts to new regulationsCEO Change & Free AI Powered Buy and Sell Recommendations - newser.com
Visual analytics tools that track Citius Pharmaceuticals Inc. performanceMarket Movement Recap & Community Supported Trade Ideas - newser.com
How Citius Pharmaceuticals Inc. (47N0) stock moves in volatile trading sessions2025 Historical Comparison & Reliable Intraday Trade Plans - newser.com
Applying Elliott Wave Theory to Citius Pharmaceuticals Inc.Bull Run & Risk Managed Trade Strategies - newser.com
Is Citius Pharmaceuticals Inc. (47N0) stock undervalued at current price2025 Momentum Check & Reliable Intraday Trade Plans - newser.com
Is Citius Pharmaceuticals Inc. (47N0) stock a contrarian opportunityJuly 2025 Catalysts & Capital Efficiency Focused Strategies - newser.com
Is Citius Pharmaceuticals Inc. stock attractive for passive investors - newser.com
Citius Pharmaceuticals Inc. stock chart pattern explained2025 Volatility Report & Safe Capital Growth Stock Tips - newser.com
Is Citius Pharmaceuticals Inc. stock positioned for long term growth2025 Key Lessons & Reliable Breakout Forecasts - newser.com
Is Citius Pharmaceuticals Inc. (47N0) stock in buy zone after pullback2025 Biggest Moves & Low Risk High Win Rate Picks - newser.com
Full technical analysis of Citius Pharmaceuticals Inc. stockWeekly Investment Report & Weekly Hot Stock Watchlists - newser.com
Is Citius Pharmaceuticals Inc. stock a buy before product launchesIndex Update & Fast Exit/Entry Strategy Plans - newser.com
Can a trend reversal in Citius Pharmaceuticals Inc. lead to recoveryJuly 2025 Drop Watch & Accurate Buy Signal Alerts - newser.com
What Wall Street predicts for Citius Pharmaceuticals Inc. stock priceOil Prices & High Yield Stock Recommendations - newser.com
Why Citius Pharmaceuticals Inc. stock could outperform in 20252025 Retail Activity & AI Forecasted Stock Moves - newser.com
Is Citius Pharmaceuticals Inc. (47N0) stock considered safe havenMarket Volume Report & Weekly High Momentum Picks - newser.com
Should you wait for a breakout in Citius Pharmaceuticals Inc.Market Risk Report & Safe Entry Momentum Stock Tips - newser.com
Can Citius Pharmaceuticals Inc. stock sustain market leadershipStop Loss & Fast Momentum Entry Tips - newser.com
What MACD and RSI say about Citius Pharmaceuticals Inc.Weekly Trend Report & Accurate Intraday Trading Signals - newser.com
Has Citius Pharmaceuticals Inc. found a price floor2025 Major Catalysts & Fast Exit and Entry Strategy Plans - newser.com
Heatmap analysis for Citius Pharmaceuticals Inc. and competitors2025 AllTime Highs & Low Risk Growth Stock Ideas - newser.com
Citius Pharmaceuticals Inc (CTXR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.25%
0.68%
자본화:
|
볼륨(24시간):